Advertisement

Survival and clinical outcome after endoscopic duodenal stent placement for malignant gastric outlet obstruction: comparison of pancreatic cancer and nonpancreatic cancer

Published:April 04, 2015DOI:https://doi.org/10.1016/j.gie.2015.01.026

      Background

      Data on endoscopic stenting of malignant gastric outlet obstruction (GOO) are based on studies predominantly involving patients with pancreatic adenocarcinoma.

      Objective

      To compare survival and clinical outcome after stent placement for GOO due to pancreatic cancer compared with nonpancreatic cancer.

      Design

      Retrospective study.

      Setting

      Single tertiary hospital.

      Patients

      A total of 292 patients with malignant GOO.

      Intervention

      Stent placement.

      Main Outcome Measurements

      Post–stent placement survival and clinical outcome.

      Results

      In 196 patients with pancreatic cancer and 96 with nonpancreatic cancer, median post–stent placement survival was similar (2.7 months in pancreatic cancer vs 2.4 months in nonpancreatic cancer). Overall survival was shorter in patients with pancreatic cancer (13.7 vs 17.1 months; P = .004). Clinical success rates at 2 months (71% vs 91%) and reintervention rates (30% vs 23%) were comparable. Post–stent placement chemotherapy and the absence of distant metastasis were associated with better post–stent placement survival in both groups (pancreatic cancer: chemotherapy vs no chemotherapy, 5.4 vs 1.5 months, P < .0001; metastasis vs no metastasis, 1.8 vs 4.6, P = .005; nonpancreatic cancer: chemotherapy vs no chemotherapy, 9.2 vs 1.8, P = .001; metastasis vs no metastasis, 2.1 vs 6.1, P = .009).

      Limitations

      Retrospective study.

      Conclusions

      In this large series of patients undergoing stent placement for malignant GOO in North America, we observed no difference in post–stent placement survival despite better overall survival in patients with nonpancreatic cancer. GOO is a marker for poor survival in malignancy, regardless of the type. Chemotherapy and the absence of distant metastasis were associated with better post–stent placement survival in both groups.

      Abbreviation:

      GOO (gastric outlet obstruction)
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Gastrointestinal Endoscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • House M.G.
        • Choti M.A.
        Palliative therapy for pancreatic/biliary cancer.
        Surg Clin North Am. 2005; 85: 359-371
        • Sarr M.G.
        • Cameron J.L.
        Surgical management of unresectable carcinoma of the pancreas.
        Surgery. 1982; 91: 123-133
        • Singh S.M.
        • Longmire Jr., W.P.
        • Reber H.A.
        Surgical palliation for pancreatic cancer. The UCLA experience.
        Ann Surg. 1990; 212: 132-139
        • Watanapa
        • Williamson R.C.
        Surgical palliation for pancreatic cancer: developments during the past two decades.
        Br J Surg. 1992; 79: 8-20
        • Egrari S.
        • O’Connell T.X.
        Role of prophylactic gastroenterostomy for unresectable pancreatic carcinoma.
        Am Surg. 1995; 61: 862-864
        • Espat N.J.
        • Brennan M.F.
        • Conlon K.C.
        Patients with laparoscopically staged unresectable pancreatic adenocarcinoma do not require subsequent surgical biliary or gastric bypass.
        J Am Coll Surg. 1999; 188: 649-657
        • Fukami N.
        • Anderson M.A.
        • Khan K.
        • et al.
        • ASGE Standards of Practice Committee
        The role of endoscopy in gastroduodenal obstruction and gastroparesis.
        Gastrointest Endosc. 2011; 74: 13-21
        • Von Hoff D.D.
        • Ervin T.
        • Arena F.P.
        • et al.
        Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
        N Engl J Med. 2013; 369: 1691-1703
        • Conroy T.
        • Desseigne F.
        • Ychou M.
        • et al.
        FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
        N Engl J Med. 2011; 364: 1817-1825
        • Loehrer Sr., P.J.
        • Feng Y.
        • Cardenes H.
        • et al.
        Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
        J Clin Oncol. 2011; 29: 4105-4112
        • Shah A.
        • Fehmi A.
        • Savides T.J.
        Increased rates of duodenal obstruction in pancreatic cancer patients receiving modern medical management.
        Dig Dis Sci. 2014; 59: 2294-2298
        • Mutignani M.
        • Tringali A.
        • Shah S.G.
        • et al.
        Combined endoscopic stent insertion in malignant biliary and duodenal obstruction.
        Endoscopy. 2007; 39: 440-447
        • Nassif T.
        • Prat F.
        • Meduri B.
        • et al.
        Endoscopic palliation of malignant gastric outlet obstruction using self-expandable metallic stents: results of a multicenter study.
        Endoscopy. 2003; 35: 483-489
        • Espinel J.
        • Sanz O.
        • Vivas S.
        • et al.
        Malignant gastrointestinal obstruction: endoscopic stenting versus surgical palliation.
        Surg Endosc. 2006; 20: 1083-1087
        • Mehta S.
        • Hindmarsh A.
        • Cheong E.
        • et al.
        Prospective randomized trial of laparoscopic gastrojejunostomy versus duodenal stenting for malignant gastric outflow obstruction.
        Surg Endosc. 2006; 20: 239-242
        • Schmidt C.
        • Gerdes H.
        • Hawkins W.
        • et al.
        A prospective observational study examining quality of life in patients with malignant gastric outlet obstruction.
        Am J Surg. 2009; 198: 92-99
        • Piesman M.
        • Kozarek R.A.
        • Brandabur J.J.
        • et al.
        Improved oral intake after palliative duodenal stenting for malignant obstruction: a prospective multicenter clinical trial.
        Am J Gastro. 2009; 104: 2404-2411
        • van Hooft J.E.
        • Dijkgraaf M.G.
        • Timmer R.
        • et al.
        Independent predictors of survival in patients with incurable malignant gastric outlet obstruction: a multicenter prospective observational study.
        Scand J Gastroenterol. 2010; 45: 1217-1222
        • Ding N.S.
        • Alexander S.
        • Swan M.P.
        • et al.
        Gastroduodenal outlet obstruction and palliative self-expandable metal stenting: a dual-centre experience.
        J Oncol. 2013; 2013: 167851
        • Gastrointestinal Tumor Study Group
        Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma.
        Cancer. 1985; 56: 2563-2568
        • Gastrointestinal Tumor Study Group
        Treatment of locally unresectable carcinoma of the pancreas: comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone.
        J Natl Cancer Inst. 1988; 80: 751-755
        • Krishnan S.
        • Rana V.
        • Janjan N.A.
        • et al.
        Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.
        Cancer. 2006; 107: 2589-2596
        • Haddock M.G.
        • Swaminathan R.
        • Foster N.R.
        • et al.
        Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.
        J Clin Oncol. 2007; 25: 2567-2572
        • Huguet F.
        • Andre T.
        • Hammel P.
        • et al.
        Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.
        J Clin Oncol. 2007; 25: 326-331
        • Chauffert B.
        • Mornex F.
        • Bonnetain F.
        • et al.
        Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study.
        Ann Oncol. 2008; 19: 1592-1599
        • Wilkowski R.
        • Boeck S.
        • Ostermaier S.
        • et al.
        Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer–a multi-centre randomized phase II study.
        Br J Cancer. 2009; 101: 1853-1859
        • Müller M.W.
        • Friess H.
        • Köninger J.
        • et al.
        Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas.
        Am J Surg. 2008; 195: 221-228
        • Cubiella J.
        • Castells A.
        • Fondevila C.
        • et al.
        Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials.
        Am J Gastroenterol. 1999; 94: 1271-1278
        • Jamal M.H.
        • Doi S.A.
        • Simoneau E.
        • et al.
        Unresectable pancreatic adenocarcinoma: do we know who survives?.
        HPB (Oxford). 2010; 12: 561-566
        • Jeurnink S.M.
        • Steyerberg E.W.
        • van Hooft J.E.
        • et al.
        Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial.
        Gastrointest Endosc. 2010; 71: 490-499
        • Pan Y.
        • Pan J.
        • Guo L.
        • et al.
        Covered versus uncovered self-expandable metallic stents for palliation of malignant gastric outlet obstruction: a systematic review and meta-analysis.
        BMC Gastroenterology. 2014; 14: 170
        • Telford J.J.
        • Carr-Locke D.L.
        • Baron T.H.
        • et al.
        Palliation of patients with malignant gastric outlet obstruction with the enteral Wallstent: outcomes from a multicenter study.
        Gastrointest Endosc. 2004; 60: 916-920
        • Kim J.H.
        • Song H.Y.
        • Shin J.H.
        • et al.
        Metallic stent placement in the palliative treatment of malignant gastroduodenal obstructions: prospective evaluation of results and factors influencing outcome in 213 patients.
        Gastrointest Endosc. 2007; 66: 256-264
        • Khashab M.
        • Alawad A.S.
        • Shin E.J.
        • et al.
        Enteral stenting versus gastrojejunostomy for palliation of malignant gastric outlet obstruction.
        Surg Endosc. 2013; 27: 2068-2075
        • van den Berg M.W.
        • Walter D.
        • Vleggaar F.P.
        • et al.
        High proximal migration rate of a partially covered “big cup” duodenal stent in patients with malignant gastric outlet obstruction.
        Endoscopy. 2014; 46: 158-161
        • Adler D.G.
        • Baron T.H.
        Endoscopic palliation of malignant gastric outlet obstruction using self-expanding metal stents: experience in 36 patients.
        Am J Gastroenterol. 2002; 97: 72-78
        • Baron T.H.
        • Harewood G.C.
        Enteral self-expandable stents.
        Gastrointest Endosc. 2003; 58: 421-433
        • Mendelsohn R.B.
        • Gerdes H.
        • Markowitz A.J.
        • et al.
        Carcinomatosis is not a contraindication to enteral stenting in selected patients with malignant gastric outlet obstruction.
        Gastrointest Endosc. 2011; 73: 1135-1140
        • Jeon H.H.
        • Park C.H.
        • Park J.C.
        • et al.
        Carcinomatosis matters: clinical outcomes and prognostic factors for clinical success of stent placement in malignant gastric outlet obstruction.
        Surg Endosc. 2014; 28: 988-995
        • Donthireddy K.R.
        • Ailawadhi S.
        • Nasser E.
        • et al.
        Malignant gastroparesis: pathogenesis and management of an underrecognized disorder.
        J Support Oncol. 2007; 5: 355-363